Entera BioENTX -2.65%23 3-Year ROIIC % is 22.29 as of Dec. 2025, which is 29% below its 10-year median of 31.38. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,321 Biotechnology companies, Entera Bio ranks better than 65.63% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Entera Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 22.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Entera Bio's 3-Year ROIIC % or its related term are showing as below:
ENTX's 3-Year ROIIC % is ranked better than 65.63% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs ENTX: 22.29
Entera Bio (NAS:ENTX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Entera Bio 3-Year ROIIC % Related Terms
Entera Bio 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Entera Bio's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENTX vs HRTX, OKYO, EDSA: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Entera Bio's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Entera Bio's 3-Year ROIIC % falls into.
Entera Bio's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -11.529 (Dec. 2025) - -13.017 (Dec. 2022) )
/
( 7.344 (Dec. 2025) - 0.669 (Dec. 2022) )
=
1.488
/
6.675
=
22.29%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Entera Bio (ENTX) has a 3-Year ROIIC % of 22.29 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entera Bio and its competitors. This is 29% below median its historical median of 31.38. According to the industry distribution chart, Entera Bio ranks #454 out of 1321 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Entera Bio's 3-Year ROIIC % too high?
Entera Bio's current 3-Year ROIIC % of 22.29 is 29% below median its 10-year median of 31.38. Based on the distribution chart, Entera Bio ranks #454 out of 1321 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's 3-Year ROIIC % compare to HRTX and OKYO?
According to the Biotechnology industry distribution chart, Entera Bio ranks #454 out of 1321 companies for 3-Year ROIIC %. This puts Entera Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Entera Bio and its competitors. Entera Bio's current 3-Year ROIIC % is 22.29, which is 29% below median its own 10-year median of 31.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current 3-Year ROIIC % of 22.29. The current 3-Year ROIIC % is 22.29, which is 29% below median its 10-year median of 31.38. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Entera Bio (ENTX), the current 3-Year ROIIC % is 22.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score
Get the complete analysis for ENTX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
